Sunday 18 October 2026 Export CYPH’s income statement to Excel — free account

Cypherpunk Technologies Inc.

In the quarter to June 2026, EPS grew 152.5% and free cash flow grew 15.5%, each against the same quarter a year earlier.

2.57 0.45 −14.90%

Follow CYPH

Alert me

Market cap: $325.5M
P/E: 4.4×
Fwd P/E: −0.7×
Dividend yield: —
F-score: n/a
Altman Z: 13.46
Beneish M: 11.15
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 6.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	—	—	—	1	—	—	—	—	1	2	—

Insider Ownership 50.33%

Capital & Financial Ratios $m

Market Cap 325.45

Revenue 1.50

Net Income (0.88)

Free Cash Flow (21.06)

Net Debt (7.62)

Current Ratio 79.19

Debt/Equity 0.00

P/E ratio 4.36

Fwd P/E (0.68)

P/S ratio 315.82

P/B ratio 3.40

Past 5Y EPS Growth —

This Y EPS Growth (121.43%)

Next Y EPS Growth 2,900.00%

Next Y revenue growth (20.00%)

Next 5Y EPS Growth 133.40%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 98.42%

10-year low 10-year high

P/B against its own 10 years 70.87%

10-year low 10-year high

EV/Sales against its own 10 years 97.64%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	71	47	14	8
Receivables	1	1	148	129
Inventory	—	—	—	—
Other	—	—	—	—
	72	48	162	138

	2023	2024	2025	Q'26
Payables	6	5	2	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	13	14	5	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	26.90%	37.64%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’21	0	0	0	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(14)	(14)	(8)	(7)	(44)
’24	(16)	(14)	(16)	(16)	(60)
’23	(13)	(10)	(10)	(10)	(44)
’22	(12)	(12)	(12)	(13)	(49)
’21	(9)	(8)	(8)	(11)	(35)
’20	(4)	(9)	(7)	(6)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	(12)	—	—	—
’25	(14)	(14)	(8)	(104)	(141)
’24	(16)	(14)	(16)	(16)	(60)
’23	(13)	(10)	(10)	(10)	(44)
’22	(12)	(12)	(12)	(13)	(49)
’21	(9)	(8)	(8)	(11)	(35)
’20	(4)	(9)	(7)	(6)	(26)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.46)	0.18	—	—	—
’25	(0.37)	(0.40)	(0.08)	0.92	0.07
’24	(0.51)	(0.52)	(0.44)	(0.37)	(1.81)
’23	(3.20)	(0.91)	(0.51)	(0.46)	(3.98)
’22	(0.90)	(1.50)	(1.30)	(1.10)	(4.80)
’21	(1.20)	(1.20)	(1.40)	(1.00)	(4.70)
’20	(5.50)	(1.20)	(0.90)	(0.90)	(6.30)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	49.00	19.12	5.73	10.20	13.30	4.00	1.24	1.68	0.22	Analyst estimates 2026–2028 Powerpack
	High	—	101.00	102.50	34.85	31.80	41.70	34.49	10.20	5.00	3.70
People
People	Employees	22	22	25	26	30	36	44	54	52	6
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.05	0.04	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	2	2	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	100.00	100.00	0.00	—	—	—
	EBT	(26)	(30)	(23)	(33)	(28)	(41)	(54)	(81)	(67)	10
	EBT margin, %	0.00	0.00	0.00	0.00	(1,834.40)	(2,707.40)	0.00	0.00	0.00	0.00
	Net income	(26)	(30)	(23)	(33)	(28)	(41)	(55)	(81)	(68)	5
	Depreciation	0	0	0	0	0	0	0	0	0	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.25	0.17	0.00	0.00	0.00	0.00
	Earnings	(27.29)	(32.70)	(16.40)	(14.70)	(6.30)	(4.70)	(4.80)	(3.98)	(1.81)	0.07
	Cash flow	(2.70)	(24.16)	(18.41)	(11.91)	(4.38)	(4.10)	(4.33)	(2.14)	(1.61)	(0.66)
	Capex	(0.02)	(0.07)	0.00	(0.04)	0.00	0.00	0.00	0.00	0.00	(1.47)
	Free cash flow	(2.71)	(24.23)	(18.41)	(11.95)	(4.37)	(4.10)	(4.33)	(2.14)	(1.61)	(2.13)
	Book value	(10.67)	12.13	6.49	(0.77)	7.86	12.57	5.20	2.94	0.93	2.32
	Shares, m	9	1	1	2	6	9	11	20	38	66
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	—	—	—	—
	P/S	—	—	—	—	88.99	185.38	—	—	—	—
	P/B	—	—	—	—	2.86	2.58	—	—	—	—
	EV/Sales	—	—	—	—	54.28	108.77	—	—	—	—
	EV/FCF	—	—	—	—	(3.14)	(4.65)	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(25)	(22)	(26)	(27)	(26)	(35)	(49)	(44)	(60)	(44)
	Capex	0	0	—	0	0	—	—	—	—	(97)
	Free cash flow	(25)	(22)	(26)	(27)	(26)	(35)	(49)	(44)	(60)	(141)
Balance, $m
Balance, $m	Working capital	(32)	22	11	(4)	45	107	57	59	34	158
	Total debt	30	—	—	1	1	0	1	—	—	—
	Net debt	(1)	(26)	(16)	(4)	(52)	(115)	(65)	(71)	(47)	(14)
	Shareholders’ equity	(100)	11	9	(2)	47	108	59	60	35	154
Returns, %
Returns, %	ROA	(664.30)	(168.76)	(96.14)	(250.80)	(121.61)	(47.12)	(58.00)	(113.72)	(111.18)	4.54
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(18.40)
	ROE	30.06	67.26	(228.05)	(895.74)	(167.42)	(52.53)	(65.48)	(136.82)	(142.43)	5.11

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021 · latest quarter Dec 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TTRX Turn Therapeutics Inc.	$345.3M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)	Compare
RLMD Relmada Therapeutics, Inc.	$341.3M	— (loss-making)	—	—	n/m	−50.06% (below 0%: shrinking)	0.00%	0.00%	Compare
IRD Opus Genetics, Inc.	$336.9M	— (loss-making)	— (loss-making)	−73.80% (below 0%: shrinking)	n/m	−16.37% (below 0%: shrinking)	100.00%	(2,182.78%)	Compare
ENTA Enanta Pharmaceuticals, Inc.	$334.1M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
CYPH Cypherpunk Technologies Inc.	$325.5M	4.4×	— (loss-making)	0.00%	n/m	+15.53% (above 0%: growing)	0.00%	0.00%
ARCT Arcturus Therapeutics Holdings Inc.	$320.3M	— (loss-making)	— (loss-making)	−89.54% (below 0%: shrinking)	n/m	−245.65% (below 0%: shrinking)	100.00%	(863.30%)	Compare
AGEN Agenus Inc.	$301.7M	2.3×	4.1×	+34.36% (above 0%: growing)	n/m	−55.25% (below 0%: shrinking)	100.00%	32.72%	Compare
Median of peers	$339.1M	—	—	−47.70%	—	−52.66%	100.00%	(258.96%)

All 614 Biotechnology stocks →

Cypherpunk Technologies Inc. (CYPH) key facts

Cypherpunk Technologies Inc. (CYPH) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CYPH traded at $2.57, a market capitalization of $325.5 million.
Return on equity was 5.11% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.